{Reference Type}: Journal Article
{Title}: A Cell-Enriched Engineered Myocardial Graft Limits Infarct Size and Improves Cardiac Function: Pre-Clinical Study in the Porcine Myocardial Infarction Model.
{Author}: Perea-Gil I;Prat-Vidal C;Gálvez-Montón C;Roura S;Llucià-Valldeperas A;Soler-Botija C;Iborra-Egea O;Díaz-Güemes I;Crisóstomo V;Sánchez-Margallo FM;Bayes-Genis A;
{Journal}: JACC Basic Transl Sci
{Volume}: 1
{Issue}: 5
{Year}: Aug 2016
{Factor}: 9.531
{DOI}: 10.1016/j.jacbts.2016.06.005
{Abstract}: Myocardial infarction (MI) remains a dreadful disease around the world, causing irreversible sequelae that shorten life expectancy and reduce quality of life despite current treatment. Here, the authors engineered a cell-enriched myocardial graft, composed of a decellularized myocardial matrix refilled with adipose tissue-derived progenitor cells (EMG-ATDPC). Once applied over the infarcted area in the swine MI model, the EMG-ATDPC improved cardiac function, reduced infarct size, attenuated fibrosis progression, and promoted neovascularization of the ischemic myocardium. The beneficial effects exerted by the EMG-ATDPC and the absence of identified adverse side effects should facilitate its clinical translation as a novel MI therapy in humans.